A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants

A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants
Conditions: Atopic Dermatitis

Interventions: Drug: Rocatinlimab vial injection; Combination Product: Rocatinlimab prefilled syringe

Sponsors: Amgen

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 20, 2024Comments OffClinicalTrials.gov | Dermatology Clinical Trials | Dermatology Studies | US National Library of Medicine
Comments